allogeneic– tag –
-
Hopstem’s iPSC-Derived Neural Progenitor Cell hNPC01 Receives FDA IND Clearance and Fast Track Designation for Stroke and Traumatic Brain Injury
AllSci USA Overview Hopstem Biotechnology announced that its allogeneic iPSC-derived forebrain neural progenitor cell therapy, hNPC01, received both IND clearance and Fast Track designation from the U.S. FDA for treating chronic motor de... -
Future of CAR T-Cell Therapy: Multi-Target, Off-the-Shelf Strategies and Manufacturing Innovation to Overcome Solid Tumors
Frontiers in Molecular Medicine Global Overview While CAR T-cell therapy revolutionized hematologic cancer treatment, challenges persist in solid tumors, including antigen heterogeneity, immunosuppressive tumor microenvironments, and poo... -
Allogene’s Off-the-Shelf CAR T Cema-Cel Secures FDA RMAT and Fast Track for High-Risk LBCL First-Line Consolidation
OncLive USA Overview Allogene Therapeutics' off-the-shelf anti-CD19 CAR T-cell therapy, cemacabtagene ansegedleucel (cema-cel), received FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for first-line consoli... -
Allogene’s Off-the-Shelf CAR T, Cema-Cel, Earns FDA RMAT and Fast Track for High-Risk LBCL First-Line Consolidation
Allogene Therapeutics, Inc. USA Overview Allogene Therapeutics has secured FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for its investigational allogeneic CAR T-cell therapy, cemacabtagene ansegedleucel (... -
Reinventing CAR T-Cell Access: How Localized Manufacturing in Turkey and China is Driving Down Costs
Bookimed Turkey Overview The prohibitively high cost of CAR T-cell therapy severely limits patient access worldwide, with prices fluctuating significantly based on manufacturing and treatment location. However, localized production, nota... -
Allogeneic CAR-T Manufacturing: Unlocking Rapid, Off-the-Shelf Cancer Therapy
Liv Hospital Turkey Overview Allogeneic CAR-T cell manufacturing is poised to revolutionize cancer treatment by providing 'off-the-shelf' solutions derived from healthy donor cells. This approach dramatically shortens treatment timelines... -
FDA Approves Orca Bio’s Precision-Engineered Cell Therapy Tregzi (Orca-T) for Allogeneic Transplant in Adults with Hematological Malignancies
CliniExpert USA Overview The U.S. FDA has approved Orca Bio’s precision-engineered cell therapy, Tregzi™ (Orca-T®), for allogeneic transplant in adult patients with hematological malignancies. Tregzi is a personalized therapy manufacture... -
Aurion Biotech Unlocks Keys to Scaling Living Cell Therapies Through Commercialization of Allogeneic Corneal Endothelial Cell Therapy in Japan
Drug Discovery News USA Overview Aurion Biotech CEO Arnaud Lacoste shared critical lessons from the successful commercialization of their allogeneic corneal endothelial cell therapy in Japan, highlighting the need for robust manufacturin... -
Widespread Global Disparities in CAR T-Cell Therapy Access Highlighted; In Vivo CAR-T, Allogeneic Platforms, and Rapid Manufacturing Emerge as Potential Solutions
ASH Clinical News USA Overview Significant global disparities in CAR T-cell therapy access are attributed to high costs, manufacturing complexities, and limited healthcare infrastructure. Novel scientific strategies, including in vivo CA... -
Kincell Bio Inaugurates and Expands State-of-the-Art GMP Cell Therapy Manufacturing Facilities in Gainesville and Research Triangle Park
Kincell Bio USA Overview Kincell Bio has opened and expanded GMP cell therapy manufacturing facilities in Gainesville, Florida, and Research Triangle Park, North Carolina, designed to support both autologous and allogeneic cell therapies...
